- Home
- SPHL vs PULM Comparison
SPHL vs PULM Comparison
Compare SPHL & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPHL | PULM |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.7M |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SPHL | PULM |
|---|---|---|
| Price | $2.42 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.1K | 10.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.35 | $1.16 |
| 52 Week High | $25.11 | $5.50 |
Technical Indicators
Market Signals| Indicator | SPHL | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 35.30 |
| Support Level | $2.19 | $1.21 |
| Resistance Level | $3.04 | $1.44 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 25.29 | 11.54 |
Price Performance
Historical ComparisonAbout SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).